Program to Improve Opioid Dependance Treatment

Reckitt Benckiser Pharmaceuticals has launched Here to Help, an unique patient support program designed to improve outcomes for people in opioid dependence treatment with SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate [2 mg/0.5 mg and 8 mg/2 mg]) C-III Sublingual Tablets. By focusing on coaching and education of patients and caregivers, Here to Help is designed to assist patients in overcoming the barriers that often prevent them from being successful in treatment for prescription opioid painkiller or heroin dependence.

Although approximately 1.7 million people in the United States are affected by opioid dependence, it is a treatable brain disease that is largely unrecognized and often undertreated. The only FDA-approved controlled medicines that can be prescribed to treat opioid dependence in a doctor’s private office are SUBOXONE and SUBUTEX (buprenorphine HCl [2 mg and 8 mg]) C-III Sublingual Tablets.

The Here to Help Program, supports patients in three main ways:

Providing personal assistance from a Care Coordinator in finding a physician who is able to treat the patient with SUBOXONE. Here to Help will also facilitate patients’ gaining access to other critical professional services, such as psychosocial support, across the entire continuum of care.
Offering Care Coaches to provide personal support to patients through a series of outbound phone calls over the critical first 12 weeks of treatment; providing motivation, education, and assistance.
Presenting online tools and resources at www.HereToHelpProgram.com, which provide 24/7 support via email and the Web. These resources include an email support program, links to online and offline support groups, downloadable patient resources and tools, and much more.

“Reckitt Benckiser Pharmaceuticals is very proud to offer Here to Help to support opioid dependent patients and their families,” said Shaun Thaxter, President of Reckitt Benckiser Pharmaceuticals Inc. “The Here to Help Program was created specifically to support patients, reflecting our Company’s commitment to helping individuals who are dependent on opioids be successful in treatment and long-term recovery. Personal Care Coach support combined with online tools and resources will offer powerful assistance to individuals and their families at a time when they can truly benefit from such help. ”

If you or someone you know is dependent on prescription painkillers or heroin, please call 1-866-973-HERE (4373) or visit www.HereToHelpProgram.com for more information on how to find treatment and enroll in the Here to Help Program.

Opioid Dependence and Resources for Its Treatment

Addiction to opioids is defined as a long-term brain disease by the World Health Organization (WHO) and the National Institute on Drug Abuse (NIDA). It is a treatable medical condition that is caused by changes in the chemistry of the brain. This dependence can start with use of medicine that a doctor prescribes for serious pain but that the patient continues to use after the medical need for pain relief has passed. Or it may begin as recreational drug use with illicit opioids that spins out of control.

Individuals who need more information about opioid dependence and its treatment, either for themselves or for someone they are concerned about, have several options. In addition to the new www.HereToHelpProgram.com website, other educational materials on opioid dependence are available online at www.turntohelp.com, also provided by Reckitt Benckiser Pharmaceuticals.

About SUBOXONE Treatment for Opioid Dependence

SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate) C-III Sublingual Tablets and SUBUTEX (buprenorphine HCl) C-III Sublingual Tablets are the only FDA-approved controlled medicines that can be prescribed by doctors in their offices, under special legislation. Any qualified doctor, including family doctors, may take the training to become certified to prescribe SUBOXONE and SUBUTEX. Treatment with buprenorphine is attractive to many patients because of the privacy and convenience that office-based treatment offers.

Buprenorphine is a partial opioid agonist, which allows it to be used to treat opioid dependence for two critical reasons. First, it acts on the brain in a way similar to full opioid agonists (e.g., prescription opioid painkillers, heroin or methadone) to retain patients in treatment and reduce opioid use by largely or entirely prevent cravings and withdrawal. Second, because it is a partial opioid agonist, it does not stimulate the same level of opioid-induced brain activity as full agonists do, and thus does not produce the maximal euphoric effect of a full opioid agonist. Undistracted by the physical aspects of the disease, patients typically are able to focus on other aspects of their lives and, with appropriate psychosocial support, begin taking whatever steps are needed to rebuild their lives. SUBOXONE in conjunction with psychosocial support can improve treatment outcomes for opioid dependent patients.

source: http://www.counselormagazine.com

More Treatment & Detox Articles

The brain maintains language skills in spite of alcohol damage by drawing from other regions

Researchers know that alcoholism can damage the brain’s frontal lobes and cerebellum, regions involved in language processing. Nonetheless, alcoholics’ language skills appear to be relatively spared from alcohol’s damaging effects. New findings suggest the brain maintains language skills by drawing upon other systems that would normally be used to perform other tasks simultaneously. Prior neuroimaging….

Hells Angel Finds God at the Bottom of Bottle of Booze

Former Hells Angel Richie Kane, 52, says he found God after bottoming out on alcohol and now has a second chance at life. For most of his years, Richie Kane struggled through a living hell of physical and sexual abuse, alcoholism and membership in one of the most notorious gangs in the country. But now….

Exercise may fight addiction

New approaches for treating and preventing drug addiction range from low-tech – regular exercise – to high-tech such as experimental vaccines aimed at helping to prevent former drug users from relapsing. Nora Volkow, director of the National Institute on Drug Abuse, is just as excited about both options. Of the two, though, exercise will probably….

Treat Alcoholism and Depression Together

A new study discovers a treatment regimen combining cognitive-behavioral therapy and medications for depression and alcohol addiction improves clinical outcomes. Specifically, combining the antidepressant sertraline (Zoloft) with the alcohol dependence treatment naltrexone produced a 54 percent abstinence rate in patients with both major depression and alcohol dependence, whereas the rates were only 21 to 28….

The Role of Patient Confidentiality in Drug Treatment Centers

For many patients, the role of patient confidentiality in drug treatment centers goes far beyond the scope of simply keeping their past problems and medical situation at bay. For some, patient confidentiality is more a matter of keeping everything about them a secret to assure that their privacy is respected 100%. In drug treatment centers,….